A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS Aspira Women’s Health Inc. is dedicated to the discovery, development, and commercialization of noninvasive, AI-powered tests to aid in the diagnosis of gynecologic diseases, starting with ovarian cancer. We plan to broaden our focus to the differential diagnosis of other gynecologic diseases that typically cannot be assessed through traditional non-invasive clinical procedures. We expect to continue commercializing our existing and new technology and to distribute our tests through our decentralized technology transfer service platform, Aspira Synergy. We also intend to continue to raise public awareness regarding the higher sensitivity and negative predictive value for ovarian malignancy of Ova 1 as compared to cancer antigen 125 (“CA-125”) on its own for women with adnexal masses planned for surgery, as well as the performance of our machine learning algorithms in detecting ovarian cancer risk in different racial and ethnic populations.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 9.3M | 9.2M | 9.2M | - | - | - |
| Net Income | -11M | -13M | -17M | -30M | -32M | -18M |
| EPS | $-0.35 | $-0.93 | $-1.81 | $-57.75 | $-64.05 | $-2.70 |
| Free Cash Flow | 0 | -12M | -16M | -31M | -28M | -15M |
| ROIC | -108.9% | -234.2% | -237.8% | -141.6% | -96.3% | -135.7% |
| Gross Margin | 63.9% | 59.7% | 57.5% | - | - | - |
| Debt/Equity | 0.00 | -1.32 | -1.21 | 0.55 | 0.14 | 0.53 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -10M | -16M | -19M | -31M | -33M | -18M |
| Operating Margin | -107.7% | -177.3% | -205.9% | - | - | - |
| ROE | 0.0% | - | - | -428.2% | -104.9% | -184.2% |
| Shares Outstanding | 43M | 30M | 30M | 1M | 0M | 7M |
Aspira Women's Health Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 58.6%.
Aspira Women's Health Inc. (AWHL) has a 5-year average return on invested capital (ROIC) of -124.5%. This is below average and may indicate limited pricing power.
Aspira Women's Health Inc. (AWHL) has a market capitalization of $13M. It is classified as a small-cap stock.
Aspira Women's Health Inc. (AWHL) does not currently pay a regular dividend.
Aspira Women's Health Inc. (AWHL) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
Aspira Women's Health Inc. (AWHL) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
Aspira Women's Health Inc. (AWHL) has a net profit margin of -142.6%. The company is currently unprofitable.
Aspira Women's Health Inc. (AWHL) generated $-12 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Aspira Women's Health Inc. (AWHL) reported earnings per share (EPS) of $-0.93 in its most recent fiscal year.
Aspira Women's Health Inc. (AWHL) has a 5-year average gross margin of 58.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for Aspira Women's Health Inc. (AWHL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Aspira Women's Health Inc. (AWHL) has a book value per share of $-0.09, based on its most recent annual SEC filing.